CORTCorcept TherapeuticsRunning, no new patients
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Ovarian Neoplasm · Fallopian Tube Neoplasms · Peritoneal Neoplasms
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.4
3 insiders sold shares within a month
Since Aug 26, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 3
- Patients
- 381 (final count)
- Started
- Jun 29, 2022
- Main results expected
- Mar 31, 2025
- Fully finished
- Dec 2026
- Results posted
- Sep 25, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to 20 months
Overall Survival
Measured over: Up to 32 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.4, since 2026-08-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05257408 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC